1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,840 | 1,090 | 20:53 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.01. | Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment | 201 | Business Wire | Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to SOTIO Biotech, a... ► Artikel lesen | |
| 09.01. | SOTIO Biotech: SOTIO Advances Colorectal Cancer ADC Program, SOT109, and Licenses Fully Human Antibodies from Biocytogen for Novel Tumor Target | 232 | Business Wire | SOT109 will leverage antibodies generated with Biocytogen's proprietary RenMab platform as backbone of ADC for colorectal cancer and other gastrointestinal cancers SOTIO Biotech, a clinical-stage... ► Artikel lesen | |
| 08.01. | Biocytogen und Acepodia bündeln ihre Kräfte, um bispezifische Antikörper und Dual-Payload-ADCs zur Behandlung komplexer Tumore voranzutreiben | 240 | Business Wire | Zusammenarbeit initiiert Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten mit doppelter Nutzlast (BsAD2Cs)
Biocytogens RenLite® trifft auf Acepodias AD2C für präzise onkologische... ► Artikel lesen | |
| 07.01. | Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors | 319 | Business Wire | Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs)
Biocytogen's RenLite® meets Acepodia's AD2C for precision oncology solutions
Biocytogen... ► Artikel lesen | |
| 06.01. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT SHARE PURCHASE BY TRUSTEE PURSUANT TO SHARE AWARD SCHEME | 2 | HKEx | ||
| 18.12.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen gibt bekannt, dass Adcendo ApS die Antikörperoption ausübt, um die ADC-Entwicklung zu beschleunigen | 349 | Business Wire | Adcendo übt seine Option aus, die vollständig humanen Antikörper von Biocytogen zu nutzen, um seine ADC-Pipeline für Krebserkrankungen mit hohem ungedecktem medizinischen Bedarf weiter auszubauen... ► Artikel lesen | |
| 16.12.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development | 242 | Business Wire | Adcendo exercises its option to utilize Biocytogen's fully human antibodies to further expand its ADC pipeline for cancers with high unmet medical need
This collaboration further validates... ► Artikel lesen | |
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 11.11.24 | Ideaya pushes ahead with Biocytogen bispecific ADC bet | 2 | FierceBiotech | ||
| 11.11.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise | 335 | Business Wire | IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen's potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034)... ► Artikel lesen | |
| 11.11.24 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT IDEAYA'S NOMINATION OF DEVELOPMENT CANDIDATE IDE034, A POTENTIAL FIRST-IN-CLASS B7H3/PTK7 TOPO-I-PAYLOAD ... | 3 | HKEx | ||
| 25.09.24 | BIOCYTOGEN-B (02315): 2024 INTERIM REPORT | 1 | HKEx | ||
| 28.08.24 | BIOCYTOGEN-B (02315): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 | - | HKEx | ||
| 16.08.24 | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | 1 | HKEx | ||
| 07.08.24 | BIOCYTOGEN-B (02315): ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE SIX MONTHS ENDED JUNE 30, 2024 | 1 | HKEx | ||
| 31.07.24 | IDEAYA in license agreement with Biocytogen for antibody drug conjugate program | 1 | Seeking Alpha | ||
| 31.07.24 | Ideaya, eyeing drug combos, bags option on Biocytogen bispecific ADC in $400M deal | 2 | FierceBiotech | ||
| 31.07.24 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program | 311 | Business Wire | Biocytogen granted IDEAYA an option for an exclusive worldwide license for potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program
B7H3/PTK7... ► Artikel lesen | |
| 31.07.24 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT ENTERS INTO OPTION AND LICENSE AGREEMENT WITH IDEAYA FOR POTENTIAL FIRST-IN-CLASS B7H3/PTK7 TOPO-I-PAYLOAD ... | 2 | HKEx | ||
| 16.07.24 | SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 302 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen | |
| 16.07.24 | SOTIO Biotech: SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 290 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 1,850 | +18,67 % | Fast 200 % Kurspotenzial! Nel ASA, Evotec, BioNTech, Medigene Aktien! | Die Aktie von Medigene hat mit dem Turnaround begonnen. Neben positiven Patent-News aus Japan für das Krebs-Testis-Antigen MAGE-A4 treibt eine Kaufempfehlung das Wertpapier. So sehen Analysten mehr... ► Artikel lesen | |
| BIOFRONTERA | 2,585 | -0,19 % | Biofrontera files to sell 5.72M shares of common stock by selling shareholders | ||
| CLINUVEL | 7,180 | +1,20 % | Clinuvel Pharmaceuticals Aktie: So sehen Experten die Lage | Nach den jüngsten Entwicklungen verzeichnet die Clinuvel Pharmaceuticals Aktie weiterhin eine rückläufige Tendenz. Am 17. Januar 2025 fiel der Kurs um 0,77 Prozent auf 7,10 EUR, was die anhaltende Schwächephase... ► Artikel lesen | |
| EDITAS MEDICINE | 1,338 | -1,51 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| BLUEBIRD BIO | 7,400 | -2,37 % | bluebird bio Announces 1-for-20 Reverse Stock Split | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it will proceed with a 1-for-20 reverse stock split ("Reverse Stock... ► Artikel lesen | |
| ASEP MEDICAL | 0,032 | -12,97 % | Asep Medical wird in landesweit ausgestrahlter Dokumentarreihe präsentiert | Asep wurde für eine spezielle Dokumentarreihe mit dem Titel "Empowered, Hosted by Meg Ryan"
ausgewählt, bei der Führungspersonen aus Wissenschaft, Technologie und Medizin im Blickpunkt stehen.
... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 3,400 | +1,04 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial | - Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,232 | -0,85 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| CLEAN HARBORS | 226,00 | -2,59 % | (CLH) - Analyzing Clean Harbors' Short Interest | ||
| SPERO THERAPEUTICS | 0,813 | -2,28 % | Spero Therapeutics, Inc.: Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes | Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice... ► Artikel lesen | |
| MESOBLAST | 1,780 | +6,59 % | MESOBLAST LTD - 6-K, Report of foreign issuer | ||
| CSTONE PHARMACEUTICALS | 0,290 | -2,68 % | CStone Pharmaceuticals: Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting | CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,302 | -4,68 % | Chiesi Global, Protalix Announce EMA Validation Of Variation Submission For Pegunigalsidase Alfa | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chiesi Global Rare Diseases, a unit of Chiesi Group, and Protalix BioTherapeutics announced the European Medicines Agency has validated the Variation Submission... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 12,240 | -0,81 % | XFRA IVH,PR9,U04,6L00,2KZ0,W2B,MI70,1IY0,B1Q,PI6: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| PURPLE BIOTECH | 3,640 | +3,41 % | Purple Biotech Ltd.: Purple Biotech Reports Third Quarter 2024 Financial Results | Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified... ► Artikel lesen |
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-2,33 %) liegt der Kurs bei 0,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.
